• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·MPLT
Share

MapLight Therapeutics, Inc. Stocks

$ 33.28Last Updated 26.06.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 24.19M

$ 33.28
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

02.11.2025 22:00

OpenAI's $1 trillion listing and a rebound in the UK market: highlights of IPOs by Nov. 2

27.10.2025 15:00

Novo-backed schizophrenia drugmaker MapLight Therapeutics debuts on Nasdaq

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is 'cheap' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of MPLT is 37 and suggests 14.8% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.06.2026 03:48

OpenAI restricted access to the new version of ChatGPT at the request of the Trump administration

27.06.2026 03:12

Moderna shares hit a two-year high after a 13% surge. It's all about a new treatment

27.06.2026 01:53

The U.S. launched strikes against Iran in response to an attack on a commercial vessel in the Strait of Hormuz

27.06.2026 01:07

The Nasdaq fell 4% following the worst week of the year for semiconductor stocks

27.06.2026 00:12

Bitcoin is at a two-year low. When will it be safe to start buying it again?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026